Nearly One Million Bottles of Heart and Kidney Medications Recalled Over Foreign Substance

Massive Recall Affects Chronic Illness Medications

Amgen, Inc. has initiated a voluntary nationwide recall affecting 944,142 bottles of prescription heart and kidney medications. The California-based pharmaceutical company discovered unexpected foreign matter on tablets during routine quality inspection. The recall includes multiple formulations of Corlanor and Sensipar, two critical medications prescribed for chronic conditions. The company acted after finding contamination in a reserve sample from one of the identified lots, prompting immediate notification to federal regulators.

The U.S. Food and Drug Administration classified this action as a Class II recall, indicating the contamination could cause temporary or medically reversible adverse health consequences. However, hazard assessments conducted by both the company and regulatory authorities concluded that overall patient safety risk remains low. The California State Board of Pharmacy issued an alert confirming that the foreign matter was localized on the exterior tablet surface, over the coating, rather than integrated into the medication itself.

The pharmaceutical giant notified federal regulators after identifying the issue at its manufacturing facility. Amgen determined that the contamination occurred in the AML Building 23 packaging area. As a precautionary measure, the company recalled all lots within their expiration dates that were processed in that specific location. The recall spans tablets distributed between October 28, 2021 and December 30, 2025, representing years of production from the affected facility.

Critical Medications for Heart and Kidney Patients

Corlanor, known by its generic name ivabradine, treats adults with chronic heart failure to reduce their risk of hospitalization for worsening heart failure. The medication works by slowing the heart rate in patients whose condition cannot be adequately controlled with other treatments. Sensipar, also sold as cinacalcet hydrochloride, helps patients with chronic kidney disease and high blood calcium levels related to parathyroid gland conditions. These medications serve critical roles in managing serious, ongoing health conditions that require continuous treatment.

The recall encompasses multiple presentations of both medications. Corlanor tablets affected include 5-milligram formulations in both 14-tablet and 60-tablet bottles. Sensipar tablets in the recall include 30-milligram and 60-milligram formulations, all packaged in 30-tablet bottles. Each product carries specific NDC (National Drug Code) numbers that allow pharmacists and patients to identify affected lots.

An Amgen spokesperson confirmed the company initiated the recall following inspection of a reserve sample. The spokesperson stated that the unexpected foreign matter appeared in a small number of units. The company recalled all lots of the affected medications from retail pharmacies across the United States out of an abundance of caution, even though the contamination appeared limited in scope.

Low Health Risk But Quality Standards Unmet

“The unexpected foreign matter was localized on the exterior tablet surface, over the coating,” the California State Board of Pharmacy stated in its alert.

Amgen determined that the foreign matter presents low potential health risk to patients, though some tablets may not meet internal quality standards for appearance. The company emphasized its commitment to product quality and patient safety in its recall announcement. To date, no complaints about the issue have been reported to the company, regulators, or healthcare providers. This suggests that if contamination reached patients, it did not result in noticeable adverse effects or recognition of the foreign matter.

The recall also addresses reported Current Good Manufacturing Practice (CGMP) deviations at the Amgen facility. These federal regulations govern pharmaceutical manufacturing to ensure product quality, safety, and efficacy. CGMP violations can trigger recalls even when immediate health risks appear minimal, reflecting the pharmaceutical industry’s strict quality standards. The FDA requires companies to maintain rigorous manufacturing controls and to take swift action when deviations occur.

What Patients Should Do Now

Patients currently taking either Corlanor or Sensipar should immediately check their medication bottles for the specific NDC numbers and lot codes included in the recall. The affected Corlanor presentations carry NDC numbers 55513-800-60 and 55513-800-99. The Sensipar presentations affected bear NDC numbers 55513-073-30 and 55513-074-30. These numbers appear on the medication label and can help patients quickly determine if their prescription falls within the recall.

Anyone with recalled medication should contact their prescriber or pharmacy for guidance on next steps. Pharmacies will provide refunds or replacement medication for affected bottles. Healthcare providers can work with patients to ensure continuity of care, either by providing unaffected lots of the same medication or prescribing alternative treatments. Patients should not stop taking prescribed medications without consulting their healthcare provider, as both conditions these drugs treat require ongoing management.

The FDA encourages patients and healthcare professionals to report adverse events or quality problems related to these products. Such reports help regulators track the scope of manufacturing issues and ensure appropriate action. The agency maintains systems for monitoring drug safety even after products reach the market, relying partly on reports from healthcare providers and patients to identify emerging problems.

Pharmaceutical Industry Quality Control Under Scrutiny

This recall highlights ongoing challenges in pharmaceutical manufacturing quality control. Even established companies with extensive quality systems occasionally experience contamination events that trigger product recalls. The FDA conducts regular inspections of drug manufacturing facilities and requires companies to maintain comprehensive quality control programs. When companies identify problems through their internal monitoring, regulators expect swift voluntary recalls as Amgen initiated in this case.

The massive scale of this recall-affecting nearly one million bottles distributed over more than four years-demonstrates how a localized manufacturing problem can have widespread impact. Modern pharmaceutical supply chains distribute medications nationally within days of production, meaning a contamination event at a single facility can quickly affect patients across the country. The recall also raises questions about inspection protocols and whether earlier detection might have limited the number of affected units.

Amgen stock showed minimal reaction to the recall announcement, with shares trading at $358.33, up $5.51 or 1.56%. The market response suggests investors view this as a manageable quality issue rather than a fundamental threat to the company’s operations. Amgen remains one of the world’s largest biotechnology companies, with a diverse portfolio of medications treating serious diseases.